Login to Your Account



Nuevolution discovery platform attracts Amgen deal; $410M per target

By Michael Fitzhugh
Staff Writer

Tuesday, October 4, 2016

Amgen Inc. is tapping Nuevolution AB's Chemetics discovery platform to identify multiple small-molecule cancer and neurology candidates for difficult-to-drug targets.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription